BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
59.78
-1.59 (-2.59%)
May 13, 2025, 4:00 PM - Market closed
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,040 employees as of December 31, 2024. The number of employees decreased by 361 or -10.61% compared to the previous year.
Employees
3,040
Change (1Y)
-361
Growth (1Y)
-10.61%
Revenue / Employee
$970,469
Profits / Employee
$172,330
Market Cap
11.46B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3,040 | -361 | -10.61% |
Dec 31, 2023 | 3,401 | 319 | 10.35% |
Dec 31, 2022 | 3,082 | 37 | 1.22% |
Dec 31, 2021 | 3,045 | -14 | -0.46% |
Dec 31, 2020 | 3,059 | 58 | 1.93% |
Dec 31, 2019 | 3,001 | 152 | 5.34% |
Dec 31, 2018 | 2,849 | 268 | 10.38% |
Dec 31, 2017 | 2,581 | 288 | 12.56% |
Dec 31, 2016 | 2,293 | 135 | 6.26% |
Dec 31, 2015 | 2,158 | 477 | 28.38% |
Dec 31, 2014 | 1,681 | 340 | 25.35% |
Dec 31, 2013 | 1,341 | 252 | 23.14% |
Dec 31, 2012 | 1,089 | 87 | 8.68% |
Dec 31, 2011 | 1,002 | 131 | 15.04% |
Dec 31, 2010 | 871 | 151 | 20.97% |
Dec 31, 2009 | 720 | 71 | 10.94% |
Dec 31, 2008 | 649 | 124 | 23.62% |
Dec 31, 2007 | 525 | 115 | 28.05% |
Dec 31, 2006 | 410 | 96 | 30.57% |
Dec 31, 2005 | 314 | -45 | -12.53% |
Dec 31, 2004 | 359 | 87 | 31.99% |
Dec 31, 2003 | 272 | 53 | 24.20% |
Dec 31, 2002 | 219 | 3 | 1.39% |
Dec 31, 2001 | 216 | 42 | 24.14% |
Dec 31, 2000 | 174 | 25 | 16.78% |
Dec 31, 1999 | 149 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BMRN News
- 1 day ago - BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings - PRNewsWire
- 12 days ago - BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance - PRNewsWire
- 27 days ago - BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET - PRNewsWire
- 5 weeks ago - BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion - Seeking Alpha
- 6 weeks ago - BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria - PRNewsWire
- 7 weeks ago - BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting - PRNewsWire
- 2 months ago - BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA - PRNewsWire